

ESOPHAGEAL CANCER

SQUAMOUS CELL CARCINOMA

TALIOS

SKYSCRAPER

ELIGIBILITY CRITERIA

- **Advanced or metastatic** scc of the esophagus
- **Refractory to or intolerant to one prior line of 5FU-taxane or platinum-taxane based regimen**
- **Confirmed radiologic progression or recurrence.**
- PDL 1 positive
- ECOG PS 0-1


ELIGIBILITY CRITERIA

- **Unresectable ESCC**
- **No disease progression** after definitive CCRT
- **Stage II-IVA and stage IVB** with SCLN metastasis only(no visceral metastasis)
- **Within 3 months of completing radiotherapy.**
- PDL-1 Positive
- ECOG PS 0-1

RO7247669 2100mg IV
Q2W (n=90)

Nivolumab 240 mg IV Q2W
(n=90)

- ✓ Randomization ratio 1:1.
- ✓ Treatment until loss of clinical benefit or max 24months.



- ✓ Randomization within **1-84 days** of last dose of radiotherapy

Coordinator: Diana Omare – 0727420410
Diana.omare@aku.edu /Ext 1605

Coordinator: Yuashita Hussein-0723122062
yuashita.hussein@aku.edu /Ext 1608